Later this week, the National Lipids Association (NLA) Scientific Sessions
will begin in Chicago, Illinois, and will showcase numerous scientific and clinical data on a number of rare lipid conditions, including lysosomal acid lipase (LAL) deficiency, homozygous familial hypercholesterolemia (HoFH), and familial chylomicronemia syndrome (FCS).
Rare Disease Report
will be in attendance to provide conference coverage.
The conference begins Thursday afternoon with noteworthy presentations by Terry
Jacobson, MD, FACP, FNLA, president of the NLA and professor of Medicine at Emory University in Atlanta, Georgia, and Carl Orringer, MD, FNLA, president-elect of the NLA and professor of Medicine at the University of Miami Health System in Florida,
discussing the NLA recommendations for patient-centered management of dyslipidemia, including recommendations for the management of special populations.
Friday through Sunday will be filled with information on a variety of common and rare lipidemias. We at Rare Disease Report
will be focused on those rare lipid conditions that are often difficult to both diagnose and treat. Some of the poster titles we plan to report on include:
- A report on a 3-year-old with severe hypercholesterolemia
- An update on the long-term effect of lomitapide in HoFH
- The safety and efficacy of sebelipase alfa in LAL deficiency
- The efficacy of atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics
- 10-year Framington Risk Score in LAL deficiency
- Efficacy of pradigastat in FCS
To follow RDR
’s coverage of the NLA Scientific Sessions, go to http://www.raredr.com/conferences/nla2015